1. Articles from ncbi.nlm.nih.gov

  2. 1-24 of 1601 1 2 3 4 ... 65 66 67 »
    1. Genetic susceptibility to neuroblastoma: current knowledge and future directions.

      Genetic susceptibility to neuroblastoma: current knowledge and future directions.

      Cell Tissue Res. 2018 Mar 27;:

      Authors: Ritenour LE, Randall MP, Bosse KR, Diskin SJ

      Abstract Neuroblastoma, a malignancy of the developing peripheral nervous system that affects infants and young children, is a complex genetic disease. Over the past two decades, significant progress has been made toward understanding the genetic determinants that predispose to this often lethal childhood cancer.

      Read Full Article
      Mentions: ALK PHOX2B
    2. Alteration of Serum IgG Galactosylation as a Potential Biomarker for Diagnosis of Neuroblastoma.

      Alteration of Serum IgG Galactosylation as a Potential Biomarker for Diagnosis of Neuroblastoma.

      J Cancer. 2018;9(5):906-913

      Authors: Qin W, Pei H, Qin R, Zhao R, Han J, Zhang Z, Dong K, Ren S, Gu J

      Abstract Background: Neuroblastoma (NB) is the most frequent pediatric malignant neoplasm that originates from embryonic neural crest cells.

      Read Full Article
    3. Treatment and outcome of adult-onset neuroblastoma.

      Treatment and outcome of adult-onset neuroblastoma.

      Int J Cancer. 2018 Mar 25;:

      Authors: Suzuki M, Kushner BH, Kramer K, Basu EM, Roberts SS, Hammond WJ, LaQuaglia MP, Wolden SL, Cheung NV, Modak S

      Abstract Adult-onset of neuroblastoma is rare and little is known about its biology and clinical course. There is no established therapy for adult neuroblastoma.

      Read Full Article
    4. Induction of MEK/ERK activity by AZD8055 confers acquired resistance in neuroblastoma.

      Induction of MEK/ERK activity by AZD8055 confers acquired resistance in neuroblastoma.

      Biochem Biophys Res Commun. 2018 Mar 20;:

      Authors: Xu DQ, Toyoda H, Qi L, Morimoto M, Hanaki R, Iwamoto S, Komada Y, Hirayama M

      Abstract Mammalian target of rapamycin (mTOR) complex (mTORC) is frequently activated in diverse cancers. Although dual mTORC1/2 inhibitors are currently under development to treat various malignancies, the emergence of drug resistance has proven to be a major complication.

      Read Full Article
    5. Neuroblastoma: clinical and biological approach to risk stratification and treatment.

      Neuroblastoma: clinical and biological approach to risk stratification and treatment.

      Cell Tissue Res. 2018 Mar 23;:

      Authors: Tolbert VP, Matthay KK

      Abstract Neuroblastoma is the most common extra-cranial solid tumor of childhood and the most common in the first year of life.

      Read Full Article
      Mentions: Treatment MYCN
    6. Excellent treatment outcomes in children younger than 18 months with stage 4 MYCN nonamplified neuroblastoma.

      Excellent treatment outcomes in children younger than 18 months with stage 4 MYCN nonamplified neuroblastoma.

      Korean J Pediatr. 2018 Feb;61(2):53-58

      Authors: Kim C, Choi YB, Lee JW, Yoo KH, Sung KW, Koo HH

      Abstract Purpose: Although the prognosis is generally good in patients with intermediate-risk neuroblastoma, no consensus has been reached on the ideal treatment regimen.

      Read Full Article
    7. Prenatally detected thoracic neuroblastoma.

      Prenatally detected thoracic neuroblastoma.

      Obstet Gynecol Sci. 2018 Mar;61(2):278-281

      Authors: Park Y, Lee HJ, Jung YJ, Lee JH, Kwon JY, Kim YH

      Abstract Neuroblastoma is the most common pediatric extracranial solid tumor derived from primitive neural crest cells of the sympathetic nervous system. Although one-fifths of all neuroblastomas occurs within the thorax, thoracic neuroblastomas detected in fetus have been rarely reported.

      Read Full Article
    8. Successful Use of Extracorporeal Life Support in a Hematopoietic Stem Cell Transplant Patient with Neuroblastoma.

      Successful Use of Extracorporeal Life Support in a Hematopoietic Stem Cell Transplant Patient with Neuroblastoma.

      J Extra Corpor Technol. 2018 Mar;50(1):61-64

      Authors: Williams FZ, Vats A, Cash T, Fortenberry JD

      Abstract Respiratory failure associated with hematopoietic stem cell transplantation (HSCT) has been considered a contraindication for use of extracorporeal membrane oxygenation (ECMO) at many centers.

      Read Full Article
    9. Pediatric mandibular metastasis: A rare finding of neuroblastoma.

      Pediatric mandibular metastasis: A rare finding of neuroblastoma.

      Radiol Case Rep. 2018 Feb;13(1):289-294

      Authors: Wade G, Revels J, Hartman L, Brown W

      Abstract We present a case of metastatic neuroblastoma to the mandible in an 11-month-old patient presenting with worsening right-sided proptosis and scalp swelling after a fall 2 weeks prior. Initial evaluation with computed tomography of the head demonstrated soft tissue masses centered at the right sphenoid and right mandible.

      Read Full Article
      Mentions: Metastasis
    10. Metabolic profiling of the three neural derived embryonal pediatric tumors retinoblastoma, neuroblastoma and medulloblastoma, identifies distinct metabolic profiles.

      Metabolic profiling of the three neural derived embryonal pediatric tumors retinoblastoma, neuroblastoma and medulloblastoma, identifies distinct metabolic profiles.

      Oncotarget. 2018 Feb 16;9(13):11336-11351

      Authors: Kohe SE, Bennett CD, Gill SK, Wilson M, McConville C, Peet AC

      Read Full Article
    11. The absence of a novel intron 19-retaining ALK transcript (ALK-I19) and MYCN amplification correlates with an excellent clinical outcome in neuroblastoma patients.

      The absence of a novel intron 19-retaining ALK transcript (ALK-I19) and MYCN amplification correlates with an excellent clinical outcome in neuroblastoma patients.

      Oncotarget. 2018 Feb 13;9(12):10698-10713

      Authors: Alshareef A, Irwin MS, Gupta N, Zhang HF, Haque M, Findlay SD, Seong BKA, Lai J, Rayis M, Al-Dandan S, Lai R

      Read Full Article
      Mentions: ALK MYCN
    12. Lymphocyte apheresis for chimeric antigen receptor T-cell manufacturing in children and young adults with leukemia and neuroblastoma.

      Lymphocyte apheresis for chimeric antigen receptor T-cell manufacturing in children and young adults with leukemia and neuroblastoma.

      Transfusion. 2018 Mar 13;:

      Authors: Ceppi F, Rivers J, Annesley C, Pinto N, Park JR, Lindgren C, Mgebroff S, Linn N, Delaney M, Gardner RA

      Read Full Article
    13. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.

      Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.

      Eur J Med Chem. 2018 Mar 06;150:282-291

      Authors: Zhao C, Zang J, Ding Q, Inks ES, Xu W, Chou CJ, Zhang Y

      Abstract In the past decade, although research and development of histone deacetylase (HDAC) inhibitors as therapeutic agents have achieved great accomplishments, especially in oncology field, there is still an urgent need for the discovery of isoform-selective HDAC inhibitors considering the side effects caused by nonselective HDAC inhibitors. HDAC8, a unique class I zinc-dependent HDAC, is becoming a potential target in cancer and other diseases. In the current study ...

      Read Full Article
      Mentions: Side Effects
    14. Updates in Diagnosis, Management, and Treatment of Neuroblastoma.

      Updates in Diagnosis, Management, and Treatment of Neuroblastoma.

      Radiographics. 2018 Mar-Apr;38(2):566-580

      Authors: Swift CC, Eklund MJ, Kraveka JM, Alazraki AL

      Abstract Neuroblastoma is an embryonic tumor of the peripheral sympathetic nervous system. It is the most common extracranial solid tumor of childhood and accounts for up to 15% of all pediatric cancer fatalities.

      Read Full Article
      Mentions: Treatment
    15. Enhanced Intratumoral Delivery of SN38 as a Tocopherol Oxyacetate Prodrug Using Nanoparticles in a Neuroblastoma Xenograft Model.

      Enhanced Intratumoral Delivery of SN38 as a Tocopherol Oxyacetate Prodrug Using Nanoparticles in a Neuroblastoma Xenograft Model.

      Clin Cancer Res. 2018 Mar 07;:

      Authors: Nguyen F, Alferiev IS, Guan P, Guerrero DT, Kolla V, Moorthy GS, Chorny M, Brodeur GM

      Read Full Article
      Mentions: Nanoparticles
    16. A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment.

      A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment.

      Cell Death Differ. 2018 Mar 07;:

      Authors: Shen J, Najafi S, Stäble S, Fabian J, Koeneke E, Kolbinger FR, Wrobel JK, Meder B, Distel M, Heimburg T, Sippl W, Jung M, Peterziel H, Kranz D, Boutros M, Westermann F, Witt O, Oehme I

      Read Full Article
      Mentions: Treatment ALK
    17. Reversible LSD1 inhibition with HCI-2509 induces the p53 gene expression signature and disrupts the MYCN signature in high-risk neuroblastoma cells.

      Reversible LSD1 inhibition with HCI-2509 induces the p53 gene expression signature and disrupts the MYCN signature in high-risk neuroblastoma cells.

      Oncotarget. 2018 Feb 09;9(11):9907-9924

      Authors: Gupta S, Doyle K, Mosbruger TL, Butterfield A, Weston A, Ast A, Kaadige M, Verma A, Sharma S

      Read Full Article
      Mentions: MYCN
    18. Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells.

      Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells.

      Pharm Res. 2018 Mar 07;35(4):85

      Authors: Gholizadeh S, Dolman EM, Wieriks R, Sparidans RW, Hennink WE, Kok RJ

      Abstract PURPOSE: Sepantronium bromide (YM155) is a hydrophilic quaternary compound that cannot be administered orally due to its low oral bioavailability; it is furthermore rapidly eliminated via the kidneys.

      Read Full Article
    19. Cross-cohort analysis identifies a TEAD4 ↔ Mycn positive-feedback loop as the core regulatory element of high-risk neuroblastoma.

      Cross-cohort analysis identifies a TEAD4 ↔ MYCN positive-feedback loop as the core regulatory element of high-risk neuroblastoma.

      Cancer Discov. 2018 Mar 06;:

      Authors: Rajbhandari P, Lopez G, Capdevila C, Salvatori B, Yu J, Rodriguez-Barrueco R, Martinez D, Yarmarkovich M, Weichert-Leahey N, Abraham BJ, Alvarez MJ, Iyer A, Harenza JL, Oldridge D, De Preter K, Koster J, Asgharzadeh S, Seeger RC, Wei JS, Khan J, Vandesompele J, Mestdagh P, Versteeg R, Look AT, Young RA, Iavarone A, Lasorella A, Silva JM, Maris JM, Califano A

      Abstract High-risk neuroblastomas show a paucity of recurrent somatic mutations at diagnosis. As a result, the molecular ...

      Read Full Article
      Mentions: MYCN
    20. A rare mediastinal occurrence of neuroblastoma in an adult: case report.

      A rare mediastinal occurrence of neuroblastoma in an adult: case report.

      Sao Paulo Med J. 2018 Mar 05;:0

      Authors: Yanik F, Karamustafaoglu YA, Yoruk Y

      Abstract CONTEXT: Neuroblastoma is the most common extracranial malignant solid tumor that occurs during childhood. It arises from primitive cells and is seen in the adrenal medulla and sympathetic ganglia of the sympathetic nervous system.

      Read Full Article
    21. Wnt Signalling Drives Context-Dependent Differentiation or Proliferation in Neuroblastoma.

      Wnt Signalling Drives Context-Dependent Differentiation or Proliferation in Neuroblastoma.

      Neoplasia. 2018 Mar 02;20(4):335-350

      Authors: Szemes M, Greenhough A, Melegh Z, Malik S, Yuksel A, Catchpoole D, Gallacher K, Kollareddy M, Park JH, Malik K

      Abstract Neuroblastoma is one of the commonest and deadliest solid tumours of childhood, and is thought to result from disrupted differentiation of the developing sympathoadrenergic lineage of the neural crest.

      Read Full Article
      Mentions: MYCN
    1-24 of 1601 1 2 3 4 ... 65 66 67 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video